Company / Capital Returned to Shareholders
Amneal Pharmaceuticals, Inc. Capital Returned to Shareholders History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$183.0M
FY2020
5-year range
-
FY2016-FY2020
Trend
-51.2%
vs FY2019
Sector context
#16 of 52
Health Care
What the data says
At $183M, Amneal Pharmaceuticals, Inc.'s capital returned to shareholders ranks #16 of 52 in the Health Care sector. Capital Returned to Shareholders has fluctuated over the past 5 years, ranging from $183M in FY2020 to $375M in FY2019.
Based on SEC 10-K filings.
$183M in FY2020 with a 3-year CAGR of -21.3%.
Declined from $201M to $183M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- -21.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
-86.3% below sector average
Key checks
Key Insights
- 3-year CAGR of -21.3%, indicating a declining trend.
- In FY2020, capital returned to shareholders decreased 51.2% year-over-year.
- Ranks #16 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2019.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | $183.0M | -51.2% |
| FY2019 | $375.3M | +87.1% |
| FY2018 | $200.6M | -46.5% |
| FY2017 | $375.3M | +87.1% |
| FY2016 | $200.6M | - |
As of FY2020 · SEC 10-K · Updated Jun 30, 2026